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The sirtuin protein SIRT1 is a well studied and highly 
complex NAD
+ dependent class III histone deacetylase 
that has seemingly diverse functions in metabolism, 
aging and cancer. SIRT1 deacetylates several 
downstream effector proteins including KU70, NBS1, 
the FOXO transcription factor family, and p53, several 
of which are in response to DNA damage events 
occurring within the cell [1]. Regulation of these factors 
by SIRT1 has indicated its direct role in cell growth and 
cellular senescence, and recent advances in 
understanding the physiologic nature of SIRT1 in these 
processes have posited both growth-promoting and 
grow-inhibiting effects of the protein. 
 
The transformative properties of the Human Papilloma 
Virus (HPV) were originally exploited well over 40 
years ago as tools for elicudating mechanisms of cell 
growth control and cancerous transformation [2]. 
Indeed, the tumor suppressor p53 was first shown to be 
regulated by the ubiquitin-proteosome pathway by its 
association with the cellular ubiquitin ligase E6-AP, a 
protein upregulated by HPV E6 protein [3]. High risk 
HPV genotypes (HPV16, -18, -31,  and -33) are now 
known as direct, causative agents of cervical cancer and 
the E6 and E7 proteins are widely known to induce the 
degradation and downregulation of p53 and pRb, 
respectively, as a mechanism for commendeering the 
growth of the host cell [4]. Until now, however, it has 
been unclear what other, if any, cellular factors HPV E6  
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and E7 target for immortalizing cells. In this issue of 
Impact Aging, Allison et al. show that HPV E7 
upregulates cellular SIRT1 and induces global histone 
modifications within the cell as an additional 
mechanism for promoting cell survival and inhibiting 
apoptosis.  
 
  Significant research intensity has been placed on 
understanding the role SIRT1 has in cellular 
transformation and cancer with studies showing both 
growth-promoting and grow-inhibiting effects of the 
protein. It has been suggested that SIRT1 does not fit 
the classical definition of a bona fide tumor suppressor 
as it does not induce cell growth arrest when 
overexpressed in cell culture and has no documented 
cases of deleterious point mutations in any type of 
human tumor [5]. The growth suppressing observations 
in vivo, therefore, could be attributed to the genetic 
context of p53 [6]. In cells retaining wildtype p53, 
SIRT1 regulates and maintains p53 in an inactive state 
by deacetylating the transcription factor and promoting 
cellular senescence over apoptosis. However, in cells 
lacking p53, such as p53 null tumor cells, SIRT1 may 
lose repression from tumor suppressors such as p53 and 
HIC1 allowing for the overexpression of SIRT1. 
Several p53 negative tumor cell lines overexpress 
SIRT1 and become highly dependent on the protein as 
shown by apoptosis induction after these cells are 
treated with SIRT1 siRNA [7, 8]. The numerous p53-
   
www.impactaging.com                  278                                    AGING, March   2009, Vol.1 No.3independent functions that SIRT1 is involved with, such 
as metabolic pathways and histone modification, may 
help these cells escape an apoptotic fate and promote 
tumorigenesis.  
 
    In this issue of Impact Aging, Allison, Jiang, and 
Milner have shown for the first time that a DNA tumor 
virus targets the anti-aging protein SIRT1 and exploits 
protein function as a mechanism for promoting 
uncontrolled cell growth. It is well known that specific 
genotypes of HPV (HPV 16 and HPV 18) are causative 
agents of cervical cancer with nearly 500,000 new 
diagnoses each year [9]. Previously, it was thought that 
the major mechanisms that the virus uses to circumvent 
controlled cell growth are through the selective 
degradation of p53 and pRb, two critically important 
growth control tumor suppressors. HPV E6 recruits the 
cellular ubiquitin ligase E6-AP to ubiquitinate and 
degrade p53. By maintaining low p53 protein levels, the 
cell is unable to mount a stress response to the invading 
virus. However, previous observations indicated that a 
p53 response in cervical cancer cells by siRNA 
depletion of HPV E6 led to cell growth arrest but not 
apoptosis, indicating that another cellular pathway was 
being overcome by HPV to block apoptosis [10]. 
Allison et al. show that HPV E7 selectively upregulates 
SIRT1 in SiHa cervical cancer cells. Upregulation of 
SIRT1 provides two downstream effects: prevention of 
apoptosis, as seen in other tumor cell lines that 
overexpress SIRT1, and deacetylation of p53, thereby 
inhibiting its ability as a transcription factor to induce 
apoptosis. 
 
HPV E6 and E7 proteins are coded for by a bicistronic 
mRNA, which makes it difficult to assess the individual 
contributions of HPV E6 and E7 on cellular 
transformation. In this study, it was found that HPV E6 
and E7 could be selectively silenced by siRNA in HPV 
16-positive SiHa cells allowing for functional 
assessment of each protein separately. Interestingly, 
selective silencing of HPV E6 was not sufficient for 
apoptosis induction, whereas silencing of HPV E7 
induced apoptosis despite HPV E6-mediated p53 
suppression. These data suggest that selective targeting 
of both p53 and SIRT1 by HPV is required to block 
apoptosis and cell growth arrest as part of the 
transformation process. HPV E7 was also shown to 
upregulate global histone H3 S10 phosphorylation, 
presumably through upregulation or stabilization of 
survivin. Global chromatin modifications during 
transformation are thought to lead to chromatin 
instability
   [11] and the previously unknown direct 
and/or indirect mechanisms of HPV E7 may have a 
significant effect on cervical cell tumorigenic transition. 
Other downstream effectors of SIRT1, such as FOXO3, 
may also play a role in this transition if SIRT1 is 
constitutively expressed, since FOXO3 deacetylation 
reduces FOXO-mediated apoptosis [12-14]. 
 
The malignant transformation of cervical cells by HPV 
from a latent state is not well understood. The virus 
exists as an episomal chromosome for an indeterminate 
amount of time within a cell until cellular 
transformation occurs and the virus integrates into the 
host genome [15]. Stable integration of the DNA also 
enhances HPV E6 and E7 expression, which allows the 
virus to combat p53 and SIRT1, respectively [16]. It is 
unclear at what point of the viral lifecycle that the HPV 
E7-mediated induction of SIRT1 is important, though 
Allison et al. show that exogenous expression of HPV 
E7 in primary keratinocytes causes significant and rapid 
upregulation of SIRT1 within 48 hours, whereas siRNA 
reduction of HPV E7 in SiHa cells caused reduction of 
SIRT1 and induced apoptosis. Together, these data 
suggest a role of overexpressed SIRT1 in HPV-infected 
cervical cells for preventing apoptosis, contributing to 
cellular transformation, and in conjunction with p53 
downregulation, allowing unregulated cell growth to 
occur. 
 
HPV E6 has received intense focus in small molecule 
drug discovery for disrupting E6-mediated E6-AP 
protein induction and subsequent p53 degradation. 
However, these data would suggest that focus on HPV 
E7 is warranted as a more suitable target since siRNA-
mediated reduction of HPV E7 in SiHa cells induces 
apoptosis. Conversely, reduction of HPV E6 leads to 
p53-mediated cell growth arrest, but a full apoptotic 
response requires inhibition of both viral proteins. 
These data could have profound implications on the 
focus of drug discovery for HPV therapeutics and 
suggests a re-analysis of current target strategies. 
Though p53 is a major factor for controlling cell growth 
and is targeted by HPV E6, the current study has shown 
that HPV E7 and the upregulation of cellular SIRT1 has 
significant effects on the tumorigenic growth of HPV 
infected cervical cancer cells. Importantly, 
downregulation of HPV E7 is sufficient for inducing 
apoptosis in these cells, indicating that selective 
targeting of this protein may be an effective strategy for 
reversing cervical cancer tumor growth. 
 
The current study also provides insight into general 
regulation of SIRT1 and specific roles it may have in 
tumorigenesis and cancer. The downstream effect of 
SIRT1 overexpression and p53 degradation mediated by 
HPV E6 and E7 is reminiscent of other tumor types that 
lack functional p53 and overexpress SIRT1, a condition 
seen in several non-cervical cancer cell lines [8]. Under 
these conditions, cells become dependent on SIRT1 
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independent mechanisms that allow the cell to continue 
to grow in an uncontrolled manner. These cells are 
highly dependent on overexpressed SIRT1 and undergo 
apoptosis upon siRNA knockdown. Similarly, the HPV 
transformed SiHa cells undergo apoptosis when SIRT1 
levels are reduced by HPV E7 siRNA knockdown. 
SIRT1 may act as an anti-apoptotic factor in 
transformed cells or cancer cell lines that lack a 
functional p53. The differential effects of SIRT1 could 
therefore be specific to the genetic background of the 
cell or tumor in question and may not fit into the 
classical definitions of an oncogene or tumor suppessor.  
 
Identification of SIRT1 as a downstream target of HPV 
E7 has broad implications in understanding HPV and 
cellular transformation. HPV E6 has long been known 
for targeting p53, but HPV E7 has now been shown to 
be involved with p53 regulation as well through 
targeting SIRT1. As small DNA viruses were originally 
used as tools to understand and elucidate cancerous 
growth, they have once again provided invaluable 
insight into cellular factors involved in cellular 
transformation. This is not only important for 
developing novel therapeutics for treating HPV 
infection, but is crucial for understanding the 
physiologic function of SIRT1 in cancer and aging. Is 
SIRT1 a critical component in the viral latency to 
malignancy transition? Is SIRT1 an important anti-
apoptotic factor in transformed cells that have lost 
functional p53? Is overexpression of SIRT1 a general 
mechanism for maintaining global de-acetylation in 
tumor cells? Answering these questions will 
undoubtedly provide new insight into the molecular 
mechanisms of cellular transformation and 
tumorigenesis for both cervical cancer and other tumor 
cell types overexpressing SIRT1.    
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